Paranasal sinus inflammation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:14:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Paranasal sinus inflammation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-brensocatib-for-patients-with-chronic-rhinosinusitis-without-nasal-polyps/ Wed, 29 Apr 2026 15:05:15 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-brensocatib-for-patients-with-chronic-rhinosinusitis-without-nasal-polyps/ This clinical trial is focused on studying the effects of a medication called Brensocatib on individuals with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). Chronic Rhinosinusitis is a condition where the sinuses become inflamed for a long period, leading to symptoms like nasal congestion and discomfort. The study will compare the effectiveness of Brensocatib, taken as a film-coated tablet, at doses of 10 mg and 40 mg, with a placebo. Another medication, Mometasone, which is a nasal spray, is also involved in the study.

The purpose of the study is to evaluate how well Brensocatib can improve nasal symptoms in participants with CRSsNP. Participants will be randomly assigned to receive either Brensocatib or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for 24 weeks, during which participants will take the medication daily and have regular check-ups to monitor their symptoms and overall health.

Throughout the study, various assessments will be conducted to measure changes in nasal symptoms, such as the Sinus Total Symptom Score and Nasal Congestion Scores. Additionally, the study will monitor any adverse events, changes in clinical laboratory test results, and other health indicators. The goal is to determine if Brensocatib is a safe and effective treatment option for improving the quality of life for those suffering from CRSsNP.

]]>